SPERO THERAPEUTICS INC's ticker is SPRO and the CUSIP is 84833T103. A total of 53 filers reported holding SPERO THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $567,371 | -16.6% | 468,902 | 0.0% | 0.04% | -20.8% |
Q2 2023 | $679,908 | 0.0% | 468,902 | 0.0% | 0.05% | +17.8% |
Q1 2023 | $679,908 | -16.2% | 468,902 | 0.0% | 0.04% | -11.8% |
Q4 2022 | $811,200 | -13.5% | 468,902 | 0.0% | 0.05% | +13.3% |
Q3 2022 | $938,000 | +170.3% | 468,902 | 0.0% | 0.04% | +164.7% |
Q2 2022 | $347,000 | -91.5% | 468,902 | 0.0% | 0.02% | -92.1% |
Q1 2022 | $4,079,000 | -45.7% | 468,902 | 0.0% | 0.22% | -39.4% |
Q4 2021 | $7,507,000 | -13.0% | 468,902 | 0.0% | 0.36% | -20.4% |
Q3 2021 | $8,632,000 | +31.9% | 468,902 | 0.0% | 0.45% | +53.8% |
Q2 2021 | $6,546,000 | -5.2% | 468,902 | 0.0% | 0.29% | +1.8% |
Q1 2021 | $6,902,000 | -38.3% | 468,902 | -18.7% | 0.28% | -40.5% |
Q4 2020 | $11,182,000 | +7.6% | 576,702 | -38.1% | 0.48% | -7.2% |
Q3 2020 | $10,391,000 | -17.5% | 931,099 | 0.0% | 0.52% | -36.5% |
Q2 2020 | $12,598,000 | +67.5% | 931,099 | 0.0% | 0.81% | +62.0% |
Q1 2020 | $7,523,000 | -15.9% | 931,099 | 0.0% | 0.50% | -12.8% |
Q4 2019 | $8,948,000 | +81.2% | 931,099 | +99.8% | 0.58% | -31.9% |
Q3 2019 | $4,939,000 | -7.9% | 465,983 | 0.0% | 0.85% | +12.6% |
Q2 2019 | $5,363,000 | – | 465,983 | – | 0.75% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Atlas Venture Associates IX, LLC | 1,376,968 | $17,639,000 | 16.57% |
Aquilo Capital Management, LLC | 1,054,356 | $13,506,000 | 5.98% |
VHCP Management II, LLC | 474,015 | $6,072,000 | 1.78% |
AWM Investment Company, Inc. | 562,296 | $7,203,000 | 1.42% |
Alphabet Inc. | 1,112,473 | $14,251,000 | 0.74% |
BVF INC/IL | 460,706 | $5,902,000 | 0.66% |
DAFNA Capital Management LLC | 70,000 | $897,000 | 0.39% |
Artal Group S.A. | 600,000 | $7,686,000 | 0.31% |
Rock Springs Capital Management LP | 525,000 | $6,725,000 | 0.26% |
Orbimed Advisors | 507,471 | $6,501,000 | 0.10% |